SGMT: Sagimet Biosciences Inc.
Performance
SGMT +44.02%
Watchlist
Select an item
Summary
SGMT at a glance
SGMT returned +44.02% over the past year. Its worst drop in that year was -48.41%, smaller than 25% of stocks on Redstone, and its Sharpe ratio of 0.79 beats 65% of stocks on Redstone. It pays no dividends.
Current Drawdown
-3.04%
Rolling Volatility
96.02%
Actions
Metrics
Risk Indicators
Alpha45.64%
Beta2.04x
Sharpe0.79
Sortino1.36
Omega1.16
Calmar0.91
Martin2.58
Profile
About SGMT
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $768M
- Listed
- Jul 2023
- Employees
- 16
- Headquarters
- Foster City, CA
- Website
- sagimet.com
Comparisons